Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 4INTERVENTIONAL

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

A Multicenter, Prospective, Single-arm Exploratory Study of Prothrombin Complex Concentrate in the Treatment of Bleeding Episodes in Patients With Hemophilia A With Inhibitors

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study is a multicenter, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of prothrombin complex concentrate (PCC) in the treatment of bleeding episodes in patients with hemophilia A with inhibitors. All participants received on-demand PCC therapy during bleeding episodes, with dosing adjusted by investigators according to the type of bleeding. The recommended dose was 50 IU/kg per infusion, administered every 8-12 hours, with a maximum total daily dose not exceeding 150 IU/kg. If no effective hemostasis was achieved within 24 hours, investigators could decide to add other hemostatic agents or switch to alternative treatments.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Diagnosed with hemophilia A with inhibitors. For high-responding patients (those who have previously had an inhibitor titer \>5 BU), the inhibitor titer at enrollment must be \>0.6 BU; 2. Age between 12 and 65 years; 3. At least three joint bleeding episodes within the past six months; 4. Signed willing to sign a consent form form. Who Should NOT Join This Trial: 1. Presence of other congenital or acquired bleeding disorders; 2. Liver function tests (ALT, AST) \>2.5 times the upper limit of normal, or renal function tests (BUN, Cr) \>1.5 times the upper limit of normal; 3. Currently receiving immune tolerance induction (ITI) therapy with an inhibitor titer \<5 BU; 4. History of thrombotic events; 5. Known history of drug allergy, asthma, urticaria, or other allergic conditions; 6. Deemed unsuitable for study participation by the investigator. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Diagnosed with hemophilia A with inhibitors. For high-responding patients (those who have previously had an inhibitor titer \>5 BU), the inhibitor titer at enrollment must be \>0.6 BU; 2. Age between 12 and 65 years; 3. At least three joint bleeding episodes within the past six months; 4. Signed informed consent form. Exclusion Criteria: 1. Presence of other congenital or acquired bleeding disorders; 2. Liver function tests (ALT, AST) \>2.5 times the upper limit of normal, or renal function tests (BUN, Cr) \>1.5 times the upper limit of normal; 3. Currently receiving immune tolerance induction (ITI) therapy with an inhibitor titer \<5 BU; 4. History of thrombotic events; 5. Known history of drug allergy, asthma, urticaria, or other allergic conditions; 6. Deemed unsuitable for study participation by the investigator.

Treatments Being Tested

DRUG

PCC

On-demand PCC therapy during bleeding episodes. The recommended dose was 50 IU/kg per infusion, administered every 8-12 hours, with a maximum total daily dose not exceeding 150 IU/kg.

Locations (1)

Institute of haematology and Blood diseases hospital
Tianjin, Tianjin Municipality, China